Healthcare technology is undergoing a massive consolidation as DoseSpot and Arrive Health announce their merger to form Interra Health. This new entity aims to solve one of the most persistent friction points in American medicine: the lack of real-time price transparency when a doctor writes a prescription. By combining electronic prescribing tools with deep medical and pharmacy benefit data, the platform allows providers to see exactly what a patient will pay before they even leave the exam room. This integration eliminates the guesswork that often leads to sticker shock and prescription abandonment at the pharmacy counter.

The merger, backed by Bain Capital Tech Opportunities, creates a powerhouse projecting over $100 million in revenue by 2026. Beyond simple cost-savings, the move signals a shift toward AI-native healthcare infrastructure. The companies noted that their unified data environment is specifically designed to support the next generation of artificial intelligence tools used by clinics and digital health platforms. This ensures that AI decision-support systems have the high-quality, real-time data needed to suggest the most affordable treatment options instantly.

Currently serving 800,000 providers, Interra Health handles 50 million prescriptions annually. By integrating bidirectional data—meaning information flows both ways between payers and providers—the system aims to reduce administrative waste and improve patient adherence. As the industry moves toward greater patient responsibility for costs, these digital tools are becoming essential for navigating the complex web of insurance coverage and drug pricing. The unified platform allows providers and patients to evaluate financial options together during the initial consultation.

Healthcare technology is undergoing a massive consolidation as DoseSpot and Arrive Health announce their merger to form Interra Health. This new entity aims to solve one of the most persistent friction points in American medicine: the lack of real-time price transparency when a doctor writes a prescription. By combining electronic prescribing tools with deep medical and pharmacy benefit data, the platform allows providers to see exactly what a patient will pay before they even leave the exam room. This integration eliminates the guesswork that often leads to sticker shock and prescription abandonment at the pharmacy counter.

The merger, backed by Bain Capital Tech Opportunities, creates a powerhouse projecting over $100 million in revenue by 2026. Beyond simple cost-savings, the move signals a shift toward AI-native healthcare infrastructure. The companies noted that their unified data environment is specifically designed to support the next generation of artificial intelligence tools used by clinics and digital health platforms. This ensures that AI decision-support systems have the high-quality, real-time data needed to suggest the most affordable treatment options instantly.

Currently serving 800,000 providers, Interra Health handles 50 million prescriptions annually. By integrating bidirectional data—meaning information flows both ways between payers and providers—the system aims to reduce administrative waste and improve patient adherence. As the industry moves toward greater patient responsibility for costs, these digital tools are becoming essential for navigating the complex web of insurance coverage and drug pricing. The unified platform allows providers and patients to evaluate financial options together during the initial consultation.